MedTrace Logo

United States Pharmacovigilence Retapamulin-Prescribing

NCT01153880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2013-06-10

No results posted yet for this study

Summary

Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the United States (US), retapamulin is approved for the treatment of impetigo in persons nine or more months of age and was launched on 12 April 2007. This five-year study is designed to examine use of retapamulin in the pediatric population less than nine months of age. We will conduct an annual assessment of prescription sales claims for retapamulin using the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database. For each year of reporting, the observed frequencies of the exposure, with or without same-day, co-prescribed sales claim of mupirocin, will be identified. The study objectives are to determine the frequency of retapamulin sales in a representative US population stratified by the designated age group and to determine the frequency of same-day sale of the topical agent, mupirocin.

Conditions

  • Skin Infections, Bacterial

Interventions

DRUG

Retapamulin

Prescription sales claim of retapamulin

DRUG

Co-prescription of retapamulin and topical mupirocin

Same day prescription sales claims for retapamulin and topical mupirocin

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-08-31
Completion
2012-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153880 on ClinicalTrials.gov